Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Piperacillin/Tazobactam vs Amikacin in ICU
NCT03990467Unknown
- Sponsor
- Hospices Civils de Lyon
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Open-label, single-arm trial of piperacillin + tazobactam in sepsis and septic shock, sponsored by Hospices Civils de Lyon. Primary endpoints: Change in plasma concentration of amikacin at 24 hours, Change in plasma concentration of piperacillin at 24 hours and 10 more. Status: unknown.
02
Drugs
piperacillin + tazobactam
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT03990467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03990467.